Canakinumab for treatment of adult onset Still's disease to achieve reduction of arthritic manifestation

Trial Profile

Canakinumab for treatment of adult onset Still's disease to achieve reduction of arthritic manifestation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2017

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Adult-onset Still's disease
  • Focus Therapeutic Use
  • Acronyms CONSIDER
  • Most Recent Events

    • 19 Dec 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2021.
    • 19 Dec 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2019.
    • 25 Jul 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top